Bioreactor Market | Analysis for Future Scope, Trend, Driving Factors and Forecast 2017-2024

Sellbyville, DE -- (SBWire) -- 11/22/2018 --The Bioreactor Market set to exceed USD 1.9 billion by 2024; according to a new research report by Global Market Insights, Inc.

Personalized medicines are changing the way many diseases are identified, classified, and treated. The growing personalized medicine market that involves a focused population base will further drive the bioreactor market size. A new manufacturing technology has evolved to provide more personalized drug products such as 3D bioprinting.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/141

Technological advances in manufacturing technology should improve flexibility, quality and scalability of operations with low capital and energy requirements. Innovative methods and analytical tools are projected to enhance process robustness, accelerate scale-up to industrial production and drive efficient use of resources.

Biopharmaceuticals are individualized products with highly specific manufacturing requirements. Advanced biopharmaceutical manufacturing technologies have enabled the development of effective drug delivery systems and drug device combination products. Increased collaboration in biopharmaceutical industry through partnerships with medical device manufacturers, diagnostic developers, academic institutions should propel business growth.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
- Thermo Fisher Scientific
- PBS Biotech, Inc.
- GE Healthcare
- Merck Group
- Pall Corporation
- Sartorius Stedim Biotech
- Applikon Biotechnology
- bbi-biotech GmbH
- CerCell
- Eppendorf North America
- Solaris Biotech

Mammalian cells market revenue is estimated to exceed USD 1.5 billion by 2024. It is widely used owing to its preference to product complex therapeutic proteins and enhanced compatibility for posttranslational modifications.

Monoclonal antibodies held more than 35% of the bioreactor market share in 2016, owing to increasing use in medical therapeutics attributed to its long half-life, high specificity, predictable pharmacokinetics, low toxicity, and high dose demand. The mAb therapeutics segment should flourish over the forecast years due to promising industry pipeline.

Single use bubble column bioreactor market size should witness over 18% CAGR over the forecast years. It is extensively used for cell line development, process development, and clinical trial manufacturing wherein they enhance the overall speed and effectiveness of media and cell line development.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/141

U.S. bioreactor market size was valued at over USD 170 million in 2016 and is anticipated to witness significant growth over the coming years due to biopharmaceutical industry participants' focus on new drug development processes and growing number of strategic collaboration with academic institutions as well as venture capital firms.

Bioreactor Market, By Cell
- Mammalian cells
- Bacterial cells
- Yeast cells
- Other cells
Bioreactor Market, By Molecule
- mAbs
- Vaccine
- Recombinant protein
- Stem cell
- Gene therapy